Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can One-Sided nearsightedness predict the other Eye's fate?

NCT ID NCT07778264

Knowledge-focused Sponsor: Buddhist Tzu Chi General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study follows children aged 7-18 who have nearsightedness (myopia) in only one eye and are being treated with MiSight 1 Day contact lenses in that eye. The other, non-myopic eye is simply observed to see if and when it becomes nearsighted. If it does, standard myopia control treatments like MiSight or atropine drops are started. The goal is to learn more about how the untreated eye changes and to find clues that might help doctors decide when to start treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MiSight 1 Day contact lens (and possibly 0.05% atropine eye drops if the fellow eye becomes myopic)
What this could lead to
If successful, this could help doctors predict which children with unilateral myopia will develop myopia in the other eye, allowing earlier and more personalized treatment.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all children, and the follow-up is only 12 months, which may be too short to capture long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

children aged 7-18 years with unilateral myopia who meet all eligibility criteria and whose parents/legal guardians provide written informed consent. The myopic eye must have a cycloplegic SER of ≤ -0.75 D, while the fellow eye must have a cycloplegic SER of \> -0.50 D. The myopic eye must have cylinder ≤1.00 D and BCVA of 20/25 or better. Participants must be willing to wear MiSight® 1 Day for at least 10 hours per day and 6 days per week and complete 12 months of follow-up.

Ages

7 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 7-18 years. 2. Cycloplegic SER ≤ -0.75 D in one eye and \> -0.50 D in the fellow eye. 3. Cylinder ≤1.00 D in the myopic eye. 4. BCVA ≥20/25 (0.1 logMAR). 5. Willingness to wear MiSight® 1 Day for ≥10 hours/day and ≥6 days/week. 6. Willingness of the participant and parents to comply with the study procedures and complete 12 months of follow-up. 7. Written informed consent provided by the legal guardian. Exclusion Criteria: * Previous orthokeratology treatment. * Previous atropine treatment exceeding one month. * Previous use of other myopia-control soft contact lenses. * Keratoconus, corneal degeneration, or other corneal disease. * Amblyopia, strabismus, or other significant binocular visual dysfunction. * Cataract, glaucoma, uveitis, retinal disease, or other significant ocular disease. * Systemic connective-tissue or neurological disease affecting vision. * Known allergy to atropine or contact lens materials. * Inability to comply with scheduled visits or anticipated relocation during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anisometropia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anisometropia myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anisometropia Myopia (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.